SCHEMBL6095022

SCHEMBL6095022

O=C1c2ccccc2C(=O)N1Cc1ccccc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.64
CA12 O43570 3/20 0.55
CA2 P00918 2/20 0.55
RAB9A P51151 1/20 0.50
CASP3 P42574 1/20 0.49
GLS O94925 1/20 0.48
CA9 Q16790 2/20 0.47
CA1 P00915 1/20 0.47
PKM P14618 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1B1 Q16678 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
RECQL P46063 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
GRM5 P41594 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5430327 0.81 CHRM1 (0.63) ALDH1A1TSHR
SCHEMBL3213661 0.81 CASP3 (0.49) TYRCA12CA2CASP3GLS
SCHEMBL1363673 0.81 GAA (0.53) TYRRAB9ACASP3KMT2AMEN1
SCHEMBL29530999 0.80 KMT2A (0.53) TYRPKMKMT2AMEN1ALDH1A1
SCHEMBL29629115 0.80 GRM5 (0.52) TYRCA12CA2CASP3CA9
SCHEMBL25320410 0.80 KMT2A (0.53) TYRPKMKMT2AMEN1ALDH1A1
SCHEMBL8931780 0.80 TYR (0.46) TYRCA12CA2RAB9ACASP3
SCHEMBL14338959 0.80 RPS6KA2 (0.53) TYRCA12CA2CASP3CA9
SCHEMBL2578279 0.80 CASP3 (0.51) TYRRAB9ACASP3ALDH1A1GRM5
SCHEMBL18669095 0.80 RPS6KA2 (0.53) TYRRAB9ACASP3CYP1B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
US-6686373-B2 ANALGESICS; ANTIINFLAMMATORY AGENT WARNER-LAMBERT COMPANY LLC 2004-02-03 US disclosed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP disclosed
EP-0820455-B1 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES AVENTIS PHARMA SA (FR) 2001-10-31 EP disclosed
CN-1063180-C 5H, 10H-imidazo [1, 2 -a] indeno [1, 2 -e] pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives RHONE POULENC RORER SA (FR) 2001-03-14 CN disclosed
US-6057454-A USEFUL FOR TREATING OR PREVENTING ALL ISCHAEMIAS (SUCH AS FOCAL OR GLOBAL ISCHAEMIA) RESULTING FROM CEREBROVASCULAR DISORDERS RHONE-POULENC RORER S.A. (FR) 2000-05-02 US disclosed
US-5902803-A 5H,10H-imidazo 1,2-a!indeno 1,2-e!pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives RHONE-POULENC RORER S.A. (FR) 1999-05-11 US disclosed
CN-1180357-A 5H, 10H-imidazo [1, 2-a ] indeno [1, 2-e ] pyrazin-4-one derivatives, preparation thereof and medicaments containing same RHONE POULENC RORER SA (FR) 1998-04-29 CN disclosed
EP-0820455-A1 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES Aventis Pharma S.A. (FR) 1998-01-28 EP disclosed
WO-1997010246-A1 INDENO[1,2-e]PYRAZIN-4-ONES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1997-03-20 WO disclosed
WO-1996031511-A1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES RHONE-POULENC RORER S.A. (FR) 1996-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PRKCB, PRKCA, PRKCG TYR 3058/4885CA12 4594/4885CA2 1100/4885
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF TYR 3016/4885CA12 4486/4885CA2 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.